CXCL5 inhibition ameliorates acute kidney injury and prevents the progression from acute kidney injury to chronic kidney disease
Clinical Science · 2024
DOI: 10.1042/cs20241713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, 2024. Verfasst von Ting-Ting Chang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department and Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Acute Kidney Injury, Chemokine CXCL5, Renal Insufficiency, Chronic, Mice, Knockout. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0). Gefördert von: Veterans General Hospitals and University System of Taiwan Joint Research Program, Ministry of Science and Technology, Taiwan, National Science and Technology Council (NSTC).
Abstract (Originalsprache)
Acute kidney injury (AKI) increases the risk of chronic kidney disease (CKD). CXC motif chemokine ligand 5 (CXCL5) is up-regulated in kidney diseases. We aimed to investigate the direct effect of CXCL5 on the pathology of AKI. Serum and renal expression of CXCL5 were increased in animals with renal ischemia–reperfusion injury or unilateral ureteral obstruction. CXCL5-knockout mice exhibited reduced systemic oxidative stress and preserved renal function in the acute and chronic phases of AKI, as evidenced by reductions in serum BUN and creatinine levels, the urinary albumin-to-creatinine ratio, and the kidney-to-body weight ratio. CXCL5-knockout mice improved AKI-induced tubular injury and fibrosis, reduced renal macrophage infiltration, and reduced expression of NADPH oxidase and inflammatory and fibrotic proteins. CXCL5 activated p47 to up-regulate ROS generation and induce cellular damages through CXCR2. CXCL5 knockdown exerted antioxidative, anti-inflammatory, anti-fibrotic, and anti-apoptotic effects on hypoxia-reoxygenation-stimulated renal proximal tubular epithelial cells. Clinical data indicated elevated circulating and renal CXCL5 in CKD patients, and renal CXCL5 was correlated with increased renal fibrosis and decreased estimated glomerular filtration rate. Altogether, CXCL5 levels increased in experimental AKI and clinical CKD, and in vivo and in vitro CXCL5 inhibition may reduce acute tubular injury and prevent the subsequent progression from AKI to CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department and Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Biomedical Industry Ph.D. Program, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Cardiovascular Research Center, Taipei Medical University Hospital, Taipei, Taiwan.
- Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
- Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
ORCID-Profile: Ting-Ting Chang
Förderung
- Veterans General Hospitals and University System of Taiwan Joint Research Program
- Ministry of Science and Technology, Taiwan
- National Science and Technology Council (NSTC)
Zitieren
APA
Chang, T. T., Li, S. Y., Tsai, M. T., Chiang, C. H., Chen, C., & Chen, J. W. (2024). CXCL5 inhibition ameliorates acute kidney injury and prevents the progression from acute kidney injury to chronic kidney disease. Clinical Science. https://doi.org/10.1042/cs20241713
Vancouver
Chang TT, Li SY, Tsai MT, Chiang CH, Chen C, Chen JW. CXCL5 inhibition ameliorates acute kidney injury and prevents the progression from acute kidney injury to chronic kidney disease. Clinical Science. 2024. doi:10.1042/cs20241713
BibTeX
@article{Chang2024,
author = {Chang, Ting-Ting and Li, Szu-Yuan and Tsai, Ming-Tsun and Chiang, Chih-Hung and Chen, Ching and Chen, Jaw-Wen},
title = {CXCL5 inhibition ameliorates acute kidney injury and prevents the progression from acute kidney injury to chronic kidney disease},
journal = {Clinical Science},
year = {2024},
doi = {10.1042/cs20241713}
}
EUVIMED